194 related articles for article (PubMed ID: 21803091)
1. Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4-5 years after a previous dose.
Halperin SA; McNeil S; Langley J; Blatter M; Dionne M; Embree J; Johnson R; Latiolais T; Meekison W; Noya F; Senders S; Zickler P; Johnson DR
Vaccine; 2011 Oct; 29(46):8459-65. PubMed ID: 21803091
[TBL] [Abstract][Full Text] [Related]
2. Immune responses in adults to revaccination with a tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine 10 years after a previous dose.
Halperin SA; Scheifele D; De Serres G; Noya F; Meekison W; Zickler P; Larrivée L; Langley JM; McNeil SA; Dobson S; Jordanov E; Thakur M; Decker MD; Johnson DR
Vaccine; 2012 Jan; 30(5):974-82. PubMed ID: 22115634
[TBL] [Abstract][Full Text] [Related]
3. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
4. Randomized Controlled Trial of the Safety and Immunogenicity of Revaccination With Tetanus-Diphtheria-Acellular Pertussis Vaccine (Tdap) in Adults 10 Years After a Previous Dose.
Halperin SA; Donovan C; Marshall GS; Pool V; Decker MD; Johnson DR; Greenberg DP;
J Pediatric Infect Dis Soc; 2019 May; 8(2):105-114. PubMed ID: 29438562
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
6. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents.
Pichichero ME; Blatter MM; Kennedy WA; Hedrick J; Descamps D; Friedland LR
Pediatrics; 2006 Apr; 117(4):1084-93. PubMed ID: 16585302
[TBL] [Abstract][Full Text] [Related]
7. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?
Halperin SA; Sweet L; Baxendale D; Neatby A; Rykers P; Smith B; Zelman M; Maus D; Lavigne P; Decker MD
Pediatr Infect Dis J; 2006 Mar; 25(3):195-200. PubMed ID: 16511379
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age.
Blatter M; Friedland LR; Weston WM; Li P; Howe B
Vaccine; 2009 Jan; 27(5):765-72. PubMed ID: 19041352
[TBL] [Abstract][Full Text] [Related]
9. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
America Academy of Pediatrics Commitee on Infectious Diseases
Pediatrics; 2006 Mar; 117(3):965-78. PubMed ID: 16382131
[TBL] [Abstract][Full Text] [Related]
10. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.
Mertsola J; Van Der Meeren O; He Q; Linko-Parvinen A; Ramakrishnan G; Mannermaa L; Soila M; Pulkkinen M; Jacquet JM
Clin Infect Dis; 2010 Sep; 51(6):656-62. PubMed ID: 20704493
[TBL] [Abstract][Full Text] [Related]
11. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
12. Acellular pertussis vaccine boosters combined with diphtheria and tetanus toxoid boosters for adolescents: safety and immunogenicity assessment when preceded by different 5-dose DTaP/DTwP schedules.
Pichichero ME; Casey JR; Francis AB; Marsocci SM; Murphy M; Hoeger W; Cleary C
Clin Pediatr (Phila); 2006 Sep; 45(7):613-20. PubMed ID: 16928838
[TBL] [Abstract][Full Text] [Related]
13. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
14. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
15. Reduced-antigen, combined diphtheria, tetanus and acellular pertussis vaccine, adsorbed (Boostrix®): a review of its properties and use as a single-dose booster immunization.
McCormack PL
Drugs; 2012 Sep; 72(13):1765-91. PubMed ID: 22931522
[TBL] [Abstract][Full Text] [Related]
16. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the safety and immunogenicity of concomitant and sequential administration of an adult formulation tetanus and diphtheria toxoids adsorbed combined with acellular pertussis (Tdap) vaccine and trivalent inactivated influenza vaccine in adults.
McNeil SA; Noya F; Dionne M; Predy G; Meekison W; Ojah C; Ferro S; Mills EL; Langley JM; Halperin SA
Vaccine; 2007 Apr; 25(17):3464-74. PubMed ID: 17270320
[TBL] [Abstract][Full Text] [Related]
18. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women.
Halperin BA; Morris A; Mackinnon-Cameron D; Mutch J; Langley JM; McNeil SA; Macdougall D; Halperin SA
Clin Infect Dis; 2011 Nov; 53(9):885-92. PubMed ID: 21946190
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of SIIPL Tdap, a new tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine, in healthy subjects 4-65 years of age: A Phase II/III randomized, observer-blinded, active controlled, multicenter clinical study in Germany.
Aydin I; May M; Pisano F; Mpofu-Maetzig N; Grode L; Parekh S; Pujari P; Shewale S; Desai S; Sharma H; Rao H; Gautam M; Gairola S; Shaligram U
Vaccine; 2023 Nov; 41(46):6810-6819. PubMed ID: 37827966
[TBL] [Abstract][Full Text] [Related]
20. An open-label, randomized, multicenter study of the safety, tolerability, and immunogenicity of quadrivalent human papillomavirus (types 6/11/16/18) vaccine given concomitantly with diphtheria, tetanus, pertussis, and poliomyelitis vaccine in healthy adolescents 11 to 17 years of age.
Vesikari T; Van Damme P; Lindblad N; Pfletschinger U; Radley D; Ryan D; Vuocolo S; Haupt RM; Guris D
Pediatr Infect Dis J; 2010 Apr; 29(4):314-8. PubMed ID: 19952980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
